A Study of YM155 Plus Docetaxel in Subjects With Stage III (Unresectable) or Stage IV Melanoma
Status:
Completed
Trial end date:
2012-08-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to evaluate survival, response rate, safety and tolerability of
YM155 given in combination with docetaxel in subjects with Stage III (unresectable) and Stage
IV melanoma.